Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pp65-LAMP mRNA vaccine
- Development stage
- Phase 1
- Lead developer
- University of Florida
- Modality
- Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The **pp65-LAMP mRNA vaccine** is an investigational cancer immunotherapy consisting of mRNA encoding the cytomegalovirus (CMV) pp65 protein fused to lysosomal-associated membrane protein (LAMP), loaded into autologous dendritic cells (DCs) or monocytes via electroporation. Developed primarily by researchers at the University of Florida and Duke University, it targets CMV antigens expressed in glioblastoma multiforme (GBM) tumors to elicit antitumor CD4+ and CD8+ T-cell responses. The LAMP fusion enhances MHC class II presentation, promoting robust cellular immunity during lymphodepletion from dose-intensified temozolomide (DI-TMZ). Administered subcutaneously with GM-CSF adjuvant post-standard chemoradiation, it has shown feasibility, safety, and immune activation in phase I/II trials, with potential survival benefits in newly diagnosed GBM.[1][7][11]
- Other names
- CMV pp65-LAMP mRNA vaccineHuman CMV pp65-LAMP mRNA-pulsed autologous DCsautologous CMV-pp65-LAMP mRNA-loaded dendritic cell vaccineautologous CMV-pp65-flLAMP mRNA loaded dendritic cell vaccineautologous CMV-pp65-LAMP mRNA-loaded monocyte vaccine MT-201-GBM
02
Targets
CMV-TCR (Cytomegalovirus-specific T-cell receptor)
Beyond the preview
Go deeper on pp65-LAMP mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pp65-LAMP mRNA vaccine.